Panse Neal S, Prasath Vishnu, Arjani Simran, Quinn Patrick L, Trivedi Ronak, Chokshi Ravi J
Surgical Oncology, Rutgers University New Jersey Medical School, Newark, USA.
Internal Medicine, Montefiore Medical Center, Wakefield Campus, Bronx, USA.
Cureus. 2022 Nov 25;14(11):e31883. doi: 10.7759/cureus.31883. eCollection 2022 Nov.
Initial staging of pancreatic ductal adenocarcinoma (PDAC) is performed with computed tomography (CT). Laparoscopy with peritoneal cytology at staging can uncover occult disease undetected by CT. This case series assessed clinical course following staging laparoscopy with cytology in patients with PDAC.
This single-center study examined patients with non-metastatic PDAC diagnosed from 2017 to 2020. Patients underwent CT and subsequent laparoscopy with cytology prior to treatment. Demographics, clinicopathologic status, treatment course, and survival were compared.
Eight patients were identified. All had negative laparoscopies. Five cytologies were negative, two were atypical, and one was positive. Two patients with negative cytology received neoadjuvant chemotherapy and underwent resection, with an average follow-up time of 32.9 months since diagnosis. Of the three remaining patients with negative cytology, none underwent resection. One received delayed chemotherapy, while the others could not due to medical contraindications. The average survival was 3.5 months (n=2). Of two patients with atypical cytology, neither underwent resection. One could not receive chemotherapy due to medical contraindication, while the other was lost to follow-up shortly after diagnosis. The average survival was 1.3 months (n=1). The patient with positive cytology received definitive chemotherapy without resection and survived for 21.6 months.
The patient with positive cytology may have been spared non-therapeutic surgery. Remaining unresected patients showed poor survival, though the lack of immediate chemotherapy may contribute to this finding. Further research is needed to determine optimal candidates for invasive staging and implications of atypical cytology.
胰腺导管腺癌(PDAC)的初始分期采用计算机断层扫描(CT)进行。分期时进行的腹腔镜检查及腹腔细胞学检查可发现CT未检测到的隐匿性疾病。本病例系列评估了PDAC患者分期腹腔镜检查及细胞学检查后的临床病程。
本单中心研究检查了2017年至2020年诊断为非转移性PDAC的患者。患者在治疗前接受了CT检查及随后的腹腔镜检查和细胞学检查。比较了人口统计学、临床病理状态、治疗过程和生存率。
共确定了8例患者。所有患者腹腔镜检查均为阴性。5例细胞学检查为阴性,2例为非典型,1例为阳性。2例细胞学检查阴性的患者接受了新辅助化疗并进行了切除,自诊断以来的平均随访时间为32.9个月。其余3例细胞学检查阴性的患者均未进行切除。1例接受了延迟化疗,其他患者因医疗禁忌无法化疗。平均生存期为3.5个月(n = 2)。2例非典型细胞学检查的患者均未进行切除。1例因医疗禁忌无法接受化疗,另1例在诊断后不久失访。平均生存期为1.3个月(n = 1)。细胞学检查阳性的患者接受了确定性化疗,未进行切除,存活了21.6个月。
细胞学检查阳性的患者可能避免了非治疗性手术。其余未切除的患者生存期较差,尽管缺乏立即化疗可能是导致这一结果的原因。需要进一步研究以确定侵入性分期的最佳候选者以及非典型细胞学检查的意义。